Targeted cellular micropharmacies: Cells engineered for localized drug delivery Review
| Authors: | Gardner, T. J.; Bourne, C. M.; Dacek, M. M.; Kurtz, K.; Malviya, M.; Peraro, L.; Silberman, P. C.; Vogt, K. C.; Unti, M. J.; Brentjens, R.; Scheinberg, D. |
| Review Title: | Targeted cellular micropharmacies: Cells engineered for localized drug delivery |
| Abstract: | The recent emergence of engineered cellular therapies, such as Chimeric antigen receptor (CAR) CAR T and T cell receptor (TCR) engineered T cells, has shown great promise in the treatment of various cancers. These agents aggregate and expand exponentially at the tumor site, resulting in potent immune activation and tumor clearance. Moreover, the ability to elaborate these cells with therapeutic agents, such as antibodies, enzymes, and immunostimulatory molecules, presents an unprecedented opportunity to specifically modulate the tumor microenvironment through cell-mediated drug delivery. This unique pharmacology, combined with significant advances in synthetic biology and cell engineering, has established a new paradigm for cells as vectors for drug delivery. Targeted cellular micropharmacies (TCMs) are a revolutionary new class of living drugs, which we envision will play an important role in cancer medicine and beyond. Here, we review important advances and considerations underway in developing this promising advancement in biological therapeutics. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. |
| Keywords: | signal transduction; protein expression; unclassified drug; promoter region; review; nonhuman; drug targeting; tumor associated leukocyte; interleukin 2; unindexed drug; cancer immunotherapy; interleukin 10; b lymphocyte; gene transfer; gene vector; immunotherapy; genetic engineering; messenger rna; vitamin d; brain derived neurotrophic factor; tumor necrosis factor related apoptosis inducing ligand; gene therapy; asparaginase; adoptive cell therapy; chimeric antigen receptor; natural killer cell; mesenchymal stem cell; thymidine kinase; bone morphogenetic protein 2; retinol; cytotoxic t lymphocyte antigen 4; macrophage; cytokine release; antibody; interleukin 12; cd28 antigen; drug delivery system; tumor necrosis factor; nonviral gene therapy; programmed death 1 ligand 1; programmed death 1 receptor; carboxypeptidase; tumor microenvironment; cd47 antigen; indinavir; glial cell line derived neurotrophic factor; surface property; angiopoietin 1; transposase; synthetic biology; heparanase; pharmaceutics; cell engineering; induced pluripotent stem cell; human; surface modification; tumor necrosis factor receptor superfamily member 9; car t; armored cars; chimeric antigen receptor t cell; synthetic immunology; targeted cellular micropharmacy; tcr therapy; beta lactamase; cv 1; ta 99 |
| Journal Title: | Cancers |
| Volume: | 12 |
| Issue: | 8 |
| ISSN: | 2072-6694 |
| Publisher: | MDPI |
| Date Published: | 2020-08-01 |
| Start Page: | 2175 |
| Language: | English |
| DOI: | 10.3390/cancers12082175 |
| PROVIDER: | scopus |
| PUBMED: | 32764348 |
| PMCID: | PMC7465970 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 October 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work